Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.45 |
| ▸ | USP7 | Q93009 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23645926 | 0.82 | SOS1 (0.52) | HTR7USP7SOS1 | |
| SCHEMBL19358368 | 0.78 | USP7 (0.73) | HTR7USP7IDO1MAOBCLK4 | |
| SCHEMBL23491483 | 0.78 | HTR7 (0.66) | HTR7USP7IDO1SOS1LMNA | |
| SCHEMBL12478207 | 0.77 | HTR7 (0.60) | HTR7USP7IDO1SOS1LMNA | |
| SCHEMBL17536743 | 0.76 | LRRK2 (0.39) | HTR7USP7IDO1MAOBADORA2A | |
| SCHEMBL23645948 | 0.73 | USP7 (0.64) | HTR7USP7LMNAMAPK10 | |
| SCHEMBL10818194 | 0.71 | SOS1 (0.69) | HTR7SOS1LMNAMAPK10 | |
| SCHEMBL17696918 | 0.71 | AURKA (0.60) | IDO1CLK4ADORA2AADORA1MAPK10 | |
| SCHEMBL23998166 | 0.71 | ADORA2A (0.58) | IDO1MAOBCLK4ADORA2AADORA1 | |
| SCHEMBL30250859 | 0.71 | ADORA2A (0.58) | IDO1MAOBCLK4ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210221813-A1 | 4,6 DIHYDROPYRROLO [3,4-C] PYRAZOLE-5 (1H)-CARBONITRILE DERIVATES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (AE) | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221813-A1 | 4,6 DIHYDROPYRROLO [3,4-C] PYRAZOLE-5 (1H)-CARBONITRILE DERIVATES FOR TREATING CANCER | USP7, USP1, USP3 | HTR7 1397/4885USP7 1/4885IDO1 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.